Who can use Welireg(Belzutifan)?

Belzutifan is a novel small-molecule targeted drug developed by Merck & Co., Inc. in the United States.

Who can use Welireg(Belzutifan)?

The drug is primarily used for the treatment of renal cell carcinoma, central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors associated with Von Hippel-Lindau (VHL) disease.

Belzutifan was first approved for marketing by the U.S. FDA on August 13, 2021, and entered the Chinese market in November 2024. Currently, belzutifan has not been included in the national medical insurance coverage.

Related Columns

Belzutifan(Welireg)

Adult patients with renal cell carcinoma, central nervous system...

WeChat Scan
Free Inquiry

What is the medicine belzutifan?

Belzutifan is an innovative drug for von Hippel-Lindau (VHL) syndrome, and its unique indications and mechanism of action provide a new treatment option for patients with VHL syndrome. This article wi...

What is the storage environment of WELIREG?

Belzutifan(WELIREG) is an innovative drug that offers a new treatment option for the treatment of von Hippel-Lindau (VHL) syndrome. So, what is the storage environment for WELIREG belzutifan?What is t...

Indications for Belzutifan

Belzutifan(Welireg) is a novel therapeutic drug specifically targeting tumors associated with von Hippel-Lindau (VHL) syndrome. It inhibits tumor growth by targeting HIF-2α and is indicated for specif...

Basic information about Belzutifan

Belzutifan (trade name Welireg) is a drug specifically used to treat diseased tissues associated with von Hippel-Lindau (VHL) syndrome. This article will discuss its basic information, purchase consid...